SangStat Medical Corporation

As of September 10, 2003, SangStat Medical Corporation was acquired by Genzyme Corp. SangStat Medical Corporation, a global biopharmaceutical company, engages in the discovery, development, and marketing of therapeutic products for immunology, transplantation medicine, hematology/oncology, and autoimmune disorders. Its primary marketed products include Thymoglobulin, for the treatment of acute rejection of a kidney transplant; Gengraf® cyclosporine capsule, a potent immunosuppressive agent that inhibits the synthesis and release of the cytokine interleukin-2; Lymphoglobuline®, for the prevention and treatment of rejection episodes in kidney, heart, pancreas, or liver transplantation, as well as for treatment of aplastic anemia and in the treatment of steroid resistant graft versus host disease; and Celsior®, a storage solution for organs after removal from the donor and before transplantation into the recipient. The company’s principal products in research and development include a smaller-size cyclosporine capsule; RDP58 for the treatment of both Crohn’s disease and ulcerative colitis; and humanized polyclonal antibodies. SangStat maintains a direct sales and marketing forces in all major European markets, the United States, and Canada; and distributors throughout the rest of the world. It competes with Novartis AG; Fujisawa Pharmaceutical Co., Ltd.; Wyeth; Immunex/AHP; and Johnson & Johnson. The company was founded in 1988 and is based in Fremont, California.